Edison Investment Research - Zamanco Minerals (ZAM) Update: External factors improve during H214

Report

Edison Investment Research

Update: External factors improve during H214

Zambeef continues to make progress towards becoming one of the leading food producers across sub-Saharan Africa rather than solely in Zambia. The adverse events affecting H114 results seem to have passed. Given the resultant margin improvement, we adjust our FY14 adjusted loss estimate from $4.6m to $1.8m and our valuation range from 16-36p to 17-37p.

01/10/2014 3 EN

Underlying

Zamanco Minerals

Zamanco Minerals Limited is an Australia-based company, which continues to seek a transaction of merit capable of becoming the primary undertaking of the Company. The Company focuses on identifying and evaluating a business opportunity. It has undertaken evaluation of a range of prospects in various industries.

See profile

AU000000ZAM5 Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: Growth in cold chain business drives turnaround

During H115, Zambeef has made significant progress in improving the profitability of its core cold chain food distribution businesses. Gross profits from the beef, chicken, pork, milk, eggs and fish operations rose by 29% year on year to $21.3m (48% in kwacha terms), resulting in the group generating $0.1m profit before tax (adjusted for unrealised forex) compared with a $3.2m loss in H114. Following the disposal of the non-core Zamanita business which completed earlier this month, we reinstate our estimates and see fair value at 17-30p.

June 23, 2015 June 23, 2015 7 EN

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on Zambeef Products (ZAM). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

June 22, 2015 June 22, 2015 1 EN

Edison Investment Research

Flash note: Disposal of Zamanita completed

Zambeef has sold its Zamanita subsidiary to Cargill for US$26.4m, payable in cash. Zamanita is one of the largest edible oil and soybean meal producers in Zambia, but is no longer a core business, is capital intensive, inherently lower margin than the cold store chain activities and exposed to fluctuations in global commodity prices and foreign exchange rates. The disposal is in line with the groupâ€™s stated strategy of unlocking the value of its assets. It enables management to focus on the groupâ€™s cold store chain activities and reduces potential earnings volatility. The transaction reduc...

June 2, 2015 June 2, 2015 2 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

May 17, 2024 May 17, 2024 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

May 17, 2024 May 17, 2024 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: External factors improve during H214

Update: Growth in cold chain business drives turnaround

Update: Termination of coverage

Flash note: Disposal of Zamanita completed

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe